TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02957162

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: 3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
Study: NCT04723732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrrh mouthwash
Description: 1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 0.2% mouthwash solution of chlorhexidine gluconate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
Study: NCT00751205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Description: Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Description: Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
Study: NCT03134547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose sevoflurane group
Description: low volume volatile anesthetics (1.0%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose sevoflurane group
Description: high volume volatile anesthetics (2.5%)
Study: NCT01978236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg
Description: Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg
Description: Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
Study: NCT03337594

Intervention type: PROCEDURE
Intervention: Surgery
Description: Cardiac surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Cardiac surgery
Study: NCT01978236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2.0 mg
Description: Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
Study: NCT00275145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise at 75% of maximal capacity for approximately 2 hours per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combo
Description: Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued Sedentary lifestyle
Description: No changes
Study: NCT04233502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo melatonin
Study: NCT01552148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USguided bilateral TAP block
Description: 23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Patient Controlled Analgesia
Description: Morphine PCA i.v. (bolus 2mg, lockout 8 min)
Study: NCT00125853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 2.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol 25mg daily
Study: NCT04578899

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transvertebral magnetic stimulation
Description: Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvertebral magnetic stimulation
Description: Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
Study: NCT00548002

Intervention type: DRUG
Intervention: trovafloxacin and levofloxacin
Description: Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
Study: NCT02032264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Chromosome Screening
Description: On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Morphologically Best
Description: Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
Study: NCT02831998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZP Vehicle
Description: Apply topically.
Study: NCT00574600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAAVI DNA-C2 vaccine
Description: DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAAVI MVA-C vaccine
Description: Boost vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine
Study: NCT03168698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Study: NCT06104579

Intervention type: OTHER
Intervention: Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection
Description: Concordance between the two registers was analysed using Cohen´s Kappa.

Intervention type: OTHER
Intervention: Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection
Description: Concordance between the two registers was analysed using Cohen´s Kappa.
Study: NCT01741311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3H+ (Holistic Health for HIV)
Description: Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HHRP+ (Holistic Health Recovery Program)
Description: 12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
Study: NCT02965053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela
Study: NCT02143063

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prize contingency management on a traditional twice weekly schedule for cocaine abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management on a variable interval schedule for cocaine abstinence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care
Study: NCT03841006

Intervention type: DEVICE
Intervention: MRI
Description: dynamic MRI pelvis

Intervention type: DEVICE
Intervention: MRI
Description: dynamic MRI pelvis
Study: NCT00576823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Dose: 0.2 mg/kg/day~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Dose: 0.2 mg/kg/day~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Dose: 0.2 mg/kg/day~Route: oral
Study: NCT04470570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Education
Description: 1) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Education
Description: 1) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood-Flow Restriction Training
Description: 1) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
Study: NCT00123019

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and diet
Description: Advice and measurement only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, Weight Reducing
Description: Measurement, advice, environmental and behavioral group interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Level 1
Description: Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 2
Description: All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
Study: NCT04741854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) Therapy
Description: PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
Study: NCT03688997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator training
Description: bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator training
Description: bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
Study: NCT01654835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low blood pressure alert
Description: A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
Study: NCT01849679

Intervention type: OTHER
Intervention: Evaluation of Swallowing
Description: Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
Study: NCT03826147

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich beetroot juice
Description: Daily supplementation with \~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: Daily supplementation with \~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
Study: NCT03334695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as sterile 0.9% saline for injection.
Study: NCT04851171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureteroscopy
Description: Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semi-rigid Ureteroscopy
Description: Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
Study: NCT00806299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide / Red Grapefruit Juice
Description: Fixed sequence of loperamide 4 mg with and without red grapefruit juice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide/ White Grapefruit Juice
Description: Fixed sequence of loperamide 4 mg with and without white grapefruit juice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide / Pink Grapefruit Juice
Description: Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
Study: NCT03166397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL
Description: TIL administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL
Description: TIL administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL
Description: TIL administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
Study: NCT01552148

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Patient Controlled Analgesia
Description: Morphine PCA i.v. (bolus 2mg, lockout 8min)
Study: NCT02980510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
Study: NCT02430103

Intervention type: DRUG
Intervention: Goserelin 3.6 MG
Description: In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
Study: NCT02909881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 0 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 1 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 1.5 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
Study: NCT03166397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg up to 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT Protocol
Description: FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months.
Study: NCT02909881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 2 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
Study: NCT03199300

Intervention type: DRUG
Intervention: Anthracyclines
Description: Chemotherapy regimen containing anthracyclines.

Intervention type: DRUG
Intervention: Anthracyclines
Description: Chemotherapy regimen containing anthracyclines.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Systemic treatment including trastuzumab.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Systemic treatment including trastuzumab.

Intervention type: DRUG
Intervention: Cisplatin
Description: Chemotherapy including cisplatin.

Intervention type: DRUG
Intervention: Cisplatin
Description: Chemotherapy including cisplatin.

Intervention type: DRUG
Intervention: Bleomycin
Description: Chemotherapy including bleomycin.
Study: NCT01550016

Intervention type: OTHER
Intervention: Observation
Description: Clinical follow-up and laboratory investigations.
Study: NCT02787733

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus flavonoid
Description: Daily dose of 500mg divided over two capsules
Study: NCT03199300

Intervention type: DRUG
Intervention: Bleomycin
Description: Chemotherapy including bleomycin.
Study: NCT01990911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Medical therapy
Description: Subjects will continue on their standard medical therapy as prescribed by their treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical therapy
Description: Subjects will continue on their standard medical therapy as prescribed by their treating physician
Study: NCT02900222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic choroid plexus coagulation
Description: A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.